

In patients treated with statins, routine measurements of creatine kinase and transaminases are not helpful

The majority of statin-associated muscle symptoms are subjective myalgia in the absence of other findings, and an asymptomatic increase in transaminases (>3 times upper limit of normal) is an infrequent statin-associated side effect. Therefore, CK and transaminase levels should not be routinely measured given the unlikely impact on clinical outcomes, and the lack of established cost effectiveness. In addition, Severe statin-associated hepatotoxicity is rare, and the incidence is not impacted by routine monitoring of transaminases.

Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology, American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014; 63(25 Pt B):2889–934.

Thompson PD, Panza G, Zaleski A, et al. Statin- associated side effects. *J Am Coll Cardiol.* 2016;67: 2395–410.

Stroes ES, Thompson PD, Corsini A, et al. Statin- associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. *Eur Heart J.* 2015;36:1012–22.

Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. *JAMA.* 2016;315: 1580–90.

Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. *J Clin Lipidol.* 2015;9:758–69.

Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. *Circulation.* 2013; 127:96–103.

Dragomir A, Cote R, White M, et al. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting. *Value Health.* 2010;13:87–94.

Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010;376: 1670–81.

Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet*. 2016;388:2532–61.

Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med*. 2016;374: 2021–31.

Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. *Am Heart J*. 2014;168:6–15.